.png)
Agenzia Italiana del Farmaco
AIFA’s Director Decision DTS 115/2024 - Cessation of the period of therapeutic continuity (Allergen medicines) - AIFA’s Director Decision DTS 115/2024 - Cessation of the period of therapeutic continuity (Allergen medicines)
AIFA’s Director Decision DTS 115/2024 - Cessation of the period of therapeutic continuity (Allergen medicines)
Starting from six months after the effectiveness of the Decision, the products indicated in the attached lists (Annex A and B) to this determination and published on the AIFA institutional website cannot continue to be marketed for the purposes of therapeutic continuity.
This determination is published on the AIFA institutional website and notice is given in the Official Journal of the Italian Republic.
It takes effect from the day following the publication of the notice.
AIFA’s Director Decision DTS 115/2024 can be reached from the "Related Links" box
Published on: 05 November 2024
Contacts
Via del Tritone, 181 00187 Roma
VAT number: 08703841000
Tax code: 97345810580
IPA AIFA code: aifa_rm
IPA UCB code: UFE1TR